New collaborative research led by Roswell Park shows that treatment with immune checkpoint inhibitors (ICIs) has led to a significant improvement in survival and response rates among patients with a particularly aggressive type of kidney cancer: advanced sarcomatoid renal cell carcinoma. The study is detailed in a presentation at the ASCO 2021 virtual annual meeting.

New work from a team at Roswell Park will help guide the care of patients with neuroendocrine tumors, or NETs. Abhay Singh, MD, MPH, and colleagues have discovered a potential biomarker to predict which patients are likely to experience side effects from a new targeted radiation treatment, peptide receptor radionuclide therapy (PRRT).

Researchers at Roswell Park led the largest study to date to suggest an improving trend in pathologic complete response rates over time for U.S. cancer patients of various races. The team's findings, documented in a poster presentation at the 2021 American Society of Clinical Oncology virtual annual meeting (abstract 575), show that African Americans are more likely than patients from any other group to have remaining disease following breast cancer treatment.